Aiming to illustrate an innovation model in an emerging market, this case summarizes the successful launch of drug-eluting stents at MicroPort and the development of innovation capabilities and culture within the company. The case also demonstrates a strategic dilemma appearing after one round of effective technological innovation and, more importantly, how understanding the value system — in this case, the health care system — is key to sustaining innovation.
| Translated title of the contribution | MicroPort Scientific: An Odyssey Starting with Coronary Stents |
|---|
| Original language | Chinese (Simplified) |
|---|
| Number of pages | 17 |
|---|
| Publication status | Published - 1 Jan 2012 |
|---|
GM-14-124GM-14-124-CC现场案例2016-07-01中欧国际工商学院
- General Management
- Strategy